Press Releases

Here is an up-to-date collection of any information given to the press. It’s a big collection, so try not to look at it all in one sitting.

Press Releases

 
Press Releases
Date Title and Summary View
Jan 13, 2015
PDF
Jan 7, 2015 BOSTON, Jan. 7, 2015 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), today announced that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, will present at the 33rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 14th, 2015 at 3:30 p.m. PT at The Westin St. Francis in San Francisco, CA. To access a live audio webca...
PDF
Dec 3, 2014 BOSTON, Mass. and GERMANTOWN, Md., Dec. 3, 2014 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, and Intrexon Corporation (NYSE:XON), a leader in synthetic biology, today announced the presentation of clinical and preclinical studies from...
PDF
Oct 30, 2014 BOSTON, Oct. 30, 2014 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced financial results for the third quarter ended September 30, 2014, and provided an update on the company's product development activities. "During the third quarter, we continued to execute our strategy and advance our immuno-oncology platform, includ...
PDF
Aug 7, 2014 BOSTON, Aug. 7, 2014 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced financial results for the second quarter ended June 30, 2014, and provided an update on the company's product development activities. "ZIOPHARM, together with our channel partner Intrexon Corporation, continues to advance a portfolio of immuno-onc...
PDF
Jul 31, 2014 BOSTON and TOKYO, July 31, 2014 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. ("ZIOPHARM") (Nasdaq:ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, and Solasia Pharma K.K. ("Solasia"), a developer of oncology pharmaceuticals in-licensed for commercialization in major markets throughout the w...
PDF
Jul 22, 2014 Expansion of synthetic immuno-oncology programs to include chimeric antigen receptor T-cell (CAR-T) therapy Increased applications of RheoSwitch® platform and its unique capabilities into targeted cellular oncology products Phase I trial utilizing Ad-RTS-...
PDF
Jun 18, 2014 BOSTON, June 18, 2014 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, and Francois Lebel, M.D., Senior Vice President, Clinical Development and Medical Operations will present at the 9th Annual JMP Securities Healthcare Conference on Wednesday, June 25th, 2014 at 1...
PDF
May 22, 2014 BOSTON, May 22, 2014 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced today results demonstrating the potent anti-tumor and anti-cancer stem cell (CTC) effects of Ad-RTS-IL-12 in a glioma (brain cancer) model, and in other precl...
PDF
May 8, 2014 BOSTON, May 8, 2014 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced financial results for the first quarter ended March 31, 2014, and provided an update on the company's product development activities. "ZIOPHARM, together with our channel partner Intrexon Corporation, continues to advance a portfolio of immuno-oncology...
PDF
Page:
1
... NextLast